News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Merck & Co., Inc. CEO: Acquisitions are Key Priority for 2009
January 8, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Merck & Co.'s (MRK 29.39, -0.10, -0.3%) leader said the drug maker has the resources to make significant acquisitions, but if the company doesn't make big purchases it will return cash to shareholders through dividends or share buybacks.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Merck & Co.
MORE ON THIS TOPIC
Manufacturing
Roche licensing pact clears generic drugmakers to manufacture antiviral flu drug
May 21, 2026
·
2 min read
·
Nick Paul Taylor
Artificial intelligence
Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling
May 21, 2026
·
3 min read
·
Tristan Manalac
Deals
Lilly and Engage Bio tie the knot with $202M acquisition
May 20, 2026
·
2 min read
·
Gabrielle Masson
Deals
Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B
May 18, 2026
·
2 min read
·
Gabrielle Masson